Related Experiment Videos
[Comprehensive management of cardiovascular risk. Focusing on telmisartan]
R Ceska1, S Krutská, L Zlatohlávek
1Centrum preventivn kardiologie III. interní kliniky 1. lékarské fakulty UKa VFN Praha. rcesk@lf1.cuni.cz
Insights
Cardiovascular diseases are a major global health issue, often caused by atherosclerosis. This paper emphasizes comprehensive management of risk factors like hypertension, highlighting telmisartan
Area of Science:
- Cardiology and Internal Medicine
Background:
- Cardiovascular diseases (CVD) are a leading global health concern, with atherosclerosis as a primary underlying cause.
- Effective management of CVD requires a comprehensive approach targeting multiple risk factors.
- Dominant risk factors include hypertension, hyperlipoproteinaemia/dyslipidemia, type 2 diabetes mellitus, visceral obesity, and smoking.
Purpose of the Study:
- To focus on the prevention and timely treatment of atherosclerosis.
- To discuss the management of hypertension as a key risk factor.
- To highlight the benefits of specific antihypertensive treatments, such as telmisartan.
Main Methods:
- Review of current literature on atherosclerosis management and risk factor control.
- Discussion of therapeutic strategies for hypertension, emphasizing modern approaches.
- Focus on the role of renin-angiotensin system (RAS) blocking agents, particularly telmisartan.
Main Results:
- Comprehensive management targeting multiple risk factors is crucial for CVD prevention.
- Renin-angiotensin system (RAS) blocking agents, like telmisartan, offer benefits over traditional treatments for patients with hypertension and metabolic syndrome.
- Telmisartan is well-tolerated and has demonstrated efficacy in reducing cardiovascular risk in large studies.
Conclusions:
- Integrated management of all risk factors is essential for atherosclerosis treatment.
- Modern antihypertensive therapies, such as RAS blockers (e.g., telmisartan), are advantageous.
- Telmisartan represents a well-tolerated and effective option for reducing cardiovascular risk.
Abstract:
Cardiovascular diseases (CVD) represent a significant health problem in all countries world-wide and in the developed world, including the Czech Republic, in particular. The underlying cause in the majority of CVD patients is atherosclerosis and its complications, respectively. The present paper focuses on prevention and timely treatment of atherosclerosis. Management should be comprehensive and should target the risk factors (RF). Hypertension, hyperlipoproteinaemia and dyslipidemia (HLP and DLP), type 2 diabetes mellitus (T2DM), visceral fat obesity and cigarette smoking are the dominating RFs. Even though all RFs have to be managed simultaneously and it is not possible to focus on just one of them, for the sake of clarity, this paper discusses hypertension and the use of telmisartan, a representative of one the most up-to-date group of antihypertensives. There is a growing evidence that it is not always just a reduction of a specific risk that is important but also the mode of treatment. For example, to reduce a CV risk in a patient with hypertension but also, for example, with metabolic syndrome, it is more beneficial to treat the patient with rennin-angiotensin system (RAS) blocking agents, possibly in a combination with calcium channels antagonists, than to use "traditional" (older) treatment approach with a combination of a beta/blocker and diuretic. Among the RAS-modifying agents, ACE inhibitors and sartans are the most widely used. Among sartans, telmisartan is very well-tolerated and has evidence from a large interventional study for its effect on reducing the CV risk.
Related Concept Videos
Atherosclerosis III: Management
Hypertension V: Nursing Management
Atherosclerosis IV: Nursing Management
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care